Recent News

• 12.11.2025 - RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026
• 12.01.2025 - RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th
• 11.19.2025 - RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th
• 11.13.2025 - RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update
• 11.06.2025 - RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD
• 10.27.2025 - RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET
• 10.09.2025 - RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD

Recent Filings

• 12.08.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.14.2025 - S-3 Registration statement under Securities Act of 1933
• 11.14.2025 - 8-K Current report
• 11.14.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 11.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.13.2025 - EX-99.1 EX-99.1
• 11.13.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.13.2025 - 8-K Current report
• 11.10.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors